### Females: Immunopath

#### Treatment Groups (ppm)

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>0</th>
<th>31.3</th>
<th>62.5</th>
<th>125</th>
<th>250</th>
<th>500</th>
<th>50 mg/kg CPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocytes (10^3/µl)</td>
<td>4.756 ± 0.319 (8) *</td>
<td>5.056 ± 0.389 (7)</td>
<td>6.475 ± 0.536 (8)</td>
<td>5.611 ± 0.763 (8)</td>
<td>6.614 ± 0.641 (8)</td>
<td>6.316 ± 0.917 (5)</td>
<td>1.485 ± 0.220 (8) *</td>
</tr>
<tr>
<td>Lymphocytes (10^3/µl)</td>
<td>3.964 ± 0.268 (8) **</td>
<td>4.269 ± 0.324 (7)</td>
<td>5.480 ± 0.488 (8)</td>
<td>4.675 ± 0.631 (8)</td>
<td>5.695 ± 0.553 (8) *</td>
<td>5.266 ± 0.692 (5) *</td>
<td>1.308 ± 0.211 (8) *</td>
</tr>
<tr>
<td>Neutrophils (10^3/µl)</td>
<td>0.554 ± 0.059 (8)</td>
<td>0.539 ± 0.052 (7)</td>
<td>0.686 ± 0.071 (8)</td>
<td>0.601 ± 0.086 (8)</td>
<td>0.589 ± 0.068 (8)</td>
<td>0.754 ± 0.181 (5)</td>
<td>0.121 ± 0.006 (8) *</td>
</tr>
<tr>
<td>Monocytes (10^3/µl)</td>
<td>0.079 ± 0.006 (8) *</td>
<td>0.089 ± 0.010 (7)</td>
<td>0.100 ± 0.011 (8)</td>
<td>0.100 ± 0.015 (8)</td>
<td>0.113 ± 0.011 (8)</td>
<td>0.106 ± 0.019 (5)</td>
<td>0.010 ± 0.000 (8) *</td>
</tr>
<tr>
<td>Eosinophils (10^3/µl)</td>
<td>0.091 ± 0.008 (8)</td>
<td>0.086 ± 0.010 (7)</td>
<td>0.100 ± 0.014 (8)</td>
<td>0.118 ± 0.020 (8)</td>
<td>0.106 ± 0.013 (8)</td>
<td>0.116 ± 0.017 (5)</td>
<td>0.019 ± 0.004 (8) *</td>
</tr>
<tr>
<td>Basophils (10^3/µl)</td>
<td>0.019 ± 0.003 (8)</td>
<td>0.011 ± 0.003 (7)</td>
<td>0.019 ± 0.003 (8)</td>
<td>0.016 ± 0.003 (8)</td>
<td>0.023 ± 0.008 (8)</td>
<td>0.014 ± 0.006 (5)</td>
<td>0.001 ± 0.001 (8) *</td>
</tr>
<tr>
<td>Large Unstained Cells (10^3/µl)</td>
<td>0.049 ± 0.004 (8)</td>
<td>0.066 ± 0.010 (7)</td>
<td>0.086 ± 0.009 (8) *</td>
<td>0.103 ± 0.036 (8)</td>
<td>0.086 ± 0.026 (8)</td>
<td>0.054 ± 0.013 (5)</td>
<td>0.024 ± 0.003 (8) *</td>
</tr>
<tr>
<td>Percent Lymphocytes</td>
<td>83.43 ± 0.90 (8)</td>
<td>84.51 ± 0.39 (7)</td>
<td>84.38 ± 1.27 (8)</td>
<td>83.43 ± 0.70 (8)</td>
<td>86.08 ± 0.77 (8)</td>
<td>84.06 ± 1.18 (5)</td>
<td>86.98 ± 1.35 (8) *</td>
</tr>
<tr>
<td>Percent Neutrophils</td>
<td>11.58 ± 0.89 (8)</td>
<td>10.57 ± 0.45 (7)</td>
<td>10.80 ± 1.08 (8)</td>
<td>10.74 ± 0.65 (8)</td>
<td>9.08 ± 0.83 (8)</td>
<td>11.36 ± 1.11 (5)</td>
<td>9.01 ± 0.93 (8) *</td>
</tr>
<tr>
<td>Percent Monocytes</td>
<td>1.59 ± 0.09 (8)</td>
<td>1.71 ± 0.12 (7)</td>
<td>1.59 ± 0.16 (8)</td>
<td>1.86 ± 0.18 (8)</td>
<td>1.73 ± 0.09 (8)</td>
<td>1.70 ± 0.17 (5)</td>
<td>0.59 ± 0.05 (8) *</td>
</tr>
<tr>
<td>Percent Eosinophils</td>
<td>1.99 ± 0.17 (8)</td>
<td>1.76 ± 0.20 (7)</td>
<td>1.54 ± 0.10 (8)</td>
<td>2.09 ± 0.14 (8)</td>
<td>1.64 ± 0.11 (8)</td>
<td>1.86 ± 0.15 (5)</td>
<td>1.58 ± 0.33 (8)</td>
</tr>
<tr>
<td>Percent Basophils</td>
<td>0.38 ± 0.07 (8)</td>
<td>0.21 ± 0.03 (7)</td>
<td>0.29 ± 0.03 (8)</td>
<td>0.25 ± 0.04 (8)</td>
<td>0.31 ± 0.06 (8)</td>
<td>0.22 ± 0.05 (5)</td>
<td>0.18 ± 0.02 (8) *</td>
</tr>
<tr>
<td>Percent Large Unstained Cells</td>
<td>1.06 ± 0.08 (8)</td>
<td>1.27 ± 0.14 (7)</td>
<td>1.43 ± 0.19 (8)</td>
<td>1.26 ± 0.10 (7)</td>
<td>1.20 ± 0.25 (8)</td>
<td>0.84 ± 0.09 (5)</td>
<td>1.69 ± 0.14 (8) *</td>
</tr>
</tbody>
</table>
LEGEND

Data are displayed as mean ± SEM (N) unless otherwise noted.

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

CPS = Cyclophosphamide

** END OF REPORT **